Literature DB >> 10789961

A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer.

P Warde1, B Kroll, B O'Sullivan, J Aslanidis, E Tew-George, J Waldron, W Maxymiw, F F Liu, D Payne, B Cummings.   

Abstract

One of the major side effects of radical radiation therapy for head and neck malignancies is xerostomia, or dryness of the mouth. There is no clearly effective treatment for this condition, but we have observed that patients in our practice believe that their symptoms improve significantly when using two "over-the-counter" oral comfort products - Biotene (toothpaste, mouthwash and chewing gum) and Oralbalance gel. We decided to study these agents in a formal phase II study to evaluate their usefulness in patients with postirradiation xerostomia. Twenty-eight patients with post-irradiation xerostomia were entered on the study. All had biopsy-proven carcinoma of the nasopharynx, oropharynx, oral cavity, hypopharynx or larynx, and had received primary radiotherapy with curative intent (> or =50 Gy in 20 fractions) more than 4 months before study entry. More than 75% of both parotid glands were included in the primary radiation field. There was no clinical evidence of recurrent disease. Patients were provided with a 2-month supply of Biotene mouthwash, toothpaste, chewing gum and Oralbalance gel. Response was evaluated 1 and 2 months after study entry using a patient-completed visual analogue scale to assess the severity of xerostomia and its effects on quality of life. For analysis, the scored baseline was subtracted from the later scores to assess change. Patients with an increase of 10 mm from their baseline score on the visual analogue scale were classified as having responded to the treatment intervention, and those with an increase of > or =25 mm from their baseline score were classified as having experienced a major improvement in their symptoms. After 2 months of treatment, 15 patients (54%) reported an improvement in intraoral dryness and 10 of these patients (36%) reported a major improvement. Similar proportions of patients (46% some improvement, 25% major improvement) reported an improvement in their ability to eat normally. Seventeen patients (61%) reported an improvement in oral discomfort, and 12 of these (43%) had a major improvement in their symptoms. The results of this study suggest that the use of Biotene (mouthwash, toothpaste and chewing gum) and Oralbalance gel can improve many of the symptoms of radiation-induced xerostomia. A placebo effect could account for many of the observed improvements in symptoms, and in order to assess the role of these agents in the management of patients with postirradiation xerostomia a randomised phase III study is needed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10789961     DOI: 10.1007/s005200050286

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  15 in total

1.  Evaluation of xerostomia in hematopoietic cell transplantation by a simple capacitance method device.

Authors:  Yuko Sugiura; Yoshihiko Soga; Sachiko Nishide; Kotoe Kono; Kanayo Takahashi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2008-06-05       Impact factor: 3.603

2.  With regard to our manuscripts on the commercial saliva substitute, Oralbalance®--its formula has been changed.

Authors:  Yuko Sugiura; Yoshihiko Soga; Ichiro Tanimoto; Susumu Kokeguchi; Sachiko Morishige-Nishide; Kotoe Itami-Kono; Kanayo Takahashi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Kokoro Yamabe; Soichiro Tsutani; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2014-09-20       Impact factor: 3.603

3.  Oral health care reduces the risk of postoperative surgical site infection in inpatients with oral squamous cell carcinoma.

Authors:  Jun Sato; Jun Goto; Ayako Harahashi; Tsubasa Murata; Hironobu Hata; Yutaka Yamazaki; Akira Satoh; Ken-ichi Notani; Yoshimasa Kitagawa
Journal:  Support Care Cancer       Date:  2010-03-16       Impact factor: 3.603

4.  Efficacy of GUM® Hydral versus Biotène® Oralbalance mouthwashes plus gels on symptoms of medication-induced xerostomia: a randomized, double-blind, crossover study.

Authors:  Anna Greta Barbe; Yasmin Schmidt-Park; Stefanie Hamacher; Sonja Henny Maria Derman; Michael Johannes Noack
Journal:  Clin Oral Investig       Date:  2017-03-28       Impact factor: 3.573

5.  Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia.

Authors:  Piet Dirix; Sandra Nuyts; Vincent Vander Poorten; Pierre Delaere; Walter Van den Bogaert
Journal:  Support Care Cancer       Date:  2007-01-18       Impact factor: 3.603

6.  Evaluation of the clinical efficacy of Biotène Oral Balance in patients with secondary Sjögren's syndrome: a pilot study.

Authors:  Ardita Aliko; Adem Alushi; Argjend Tafaj; Ramazan Isufi
Journal:  Rheumatol Int       Date:  2011-09-07       Impact factor: 2.631

7.  Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation.

Authors:  Yuko Sugiura; Yoshihiko Soga; Kokoro Yamabe; Soichiro Tsutani; Ichiro Tanimoto; Hiroshi Maeda; Susumu Kokeguchi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2009-12-05       Impact factor: 3.603

Review 8.  Saliva substitutes for the treatment of radiation-induced xerostomia--a review.

Authors:  Sebastian Hahnel; Michael Behr; Gerhard Handel; Ralf Bürgers
Journal:  Support Care Cancer       Date:  2009-06-04       Impact factor: 3.603

9.  Antimicrobial effects of the saliva substitute, Oralbalance, against microorganisms from oral mucosa in the hematopoietic cell transplantation period.

Authors:  Yuko Sugiura; Yoshihiko Soga; Ichiro Tanimoto; Susumu Kokeguchi; Sachiko Nishide; Kotoe Kono; Kanayo Takahashi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Kokoro Yamabe; Soichiro Tsutani; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2008-01-16       Impact factor: 3.603

Review 10.  Cost-effectiveness landscape analysis of treatments addressing xerostomia in patients receiving head and neck radiation therapy.

Authors:  Laura S Sasportas; Drew N Hosford; Maria A Sodini; Dale J Waters; Elizabeth A Zambricki; Joëlle K Barral; Edward E Graves; Todd J Brinton; Paul G Yock; Quynh-Thu Le; Davud Sirjani
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.